BindingDB logo
myBDB logout

24 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
26871660 68 Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.EBI San Raffaele Scientific Institute
26192023 71 SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.EBI £Florida Atlantic University
24044434 71 Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.EBI Università di Pisa
19715320 87 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI University of Florida
19635666 119 Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.EBI Incyte Corporation
20638281 56 Structure and activity relationships of tartrate-based TACE inhibitors.EBI Merck Research Laboratories
21458257 87 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.EBI Merck Research Laboratories
21106451 39 Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.EBI Merck Research Laboratories
20180536 128 Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.EBI Universit£ di Pisa
20172725 49 Discovery and SAR of hydantoin TACE inhibitors.EBI Merck Research Laboratories
20022498 71 The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.EBI Schering-Plough Research Institute Cambridge
18835710 69 Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.EBI Schering Plough Research Institute
19457660 90 Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.EBI Incyte Corporation
18790648 317 Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.EBI University of Athens
18068976 132 Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.EBI Incyte Corporation
18036818 157 Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.EBI Incyte Corporation
17256836 84 Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.EBI Incyte Corporation
15546732 11 Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors.EBI Department of Life Science and National Research Laboratory of Proteolysis